Basic Dynamics of Chronic Myeloid Leukemia During Imatinib Treatment

摘要: Treatment with tyrosine kinase inhibitors, such as imatinib, have led to impressive therapy responses in the clinic. This chapter will discuss pattern of decline BCR-ABL transcript numbers during treatment, and explore different hypotheses explain them. typically results a bi-phasic numbers, where faster phase is followed by slower phase. The earliest tried this assuming that more differentiated tumor cells are susceptible drug, while stem resistant. Subsequent work showed decline, other, less common patterns found among patients, can be explained differential susceptibility drug activated quiescent cells. In addition basic cell dynamics, mathematical models also indicated transient rise anti-tumor immunity treatment could contribute determining response. Implications for strategies discussed.